Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium

Por Kindler, Hedy Lee, Wroblewski, Kristen, Wallace, James A., Hall, Michael J., Locker, Gershon, Nattam, Sreenivasa, Agamah, Edem, Stadler, Walter M., Vokes, Everett E.
Publicado no Invest New Drugs (2010)

A Phase II Study of Sorafenib in Advanced Uterine Carcinoma / Carcinosarcoma: A Trial of the Chicago, PMH, and California Phase II Consortia

Por Nimeiri, Halla S., Oza, Amit M., Morgan, Robert J., Huo, Dezheng, Elit, Laurie, Knost, James A., Wade, James L., Agamah, Edem, Vokes, Everett E., Fleming, Gini F.
Publicado em 2010

The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Car...

Por Lerario, Antonio M., Worden, Francis P., Ramm, Carole A., Hasseltine, Elizabeth A., Stadler, Walter M., Else, Tobias, Shah, Manisha H., Agamah, Edem, Rao, Krishna, Hammer, Gary D.
Publicado no Horm Cancer (2014)

Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

Por Campbell, Nicholas P., Kunnavakkam, Rangesh, Leighl, Natasha, Vincent, Mark D., Gandara, David R., Koczywas, Marianna, Gitlitz, Barbara J., Agamah, Edem, Thomas, Sachdev P., Stadler, Walter M., Vokes, Everett E., Kindler, Hedy L.
Publicado no Lung Cancer (2012)